Sweden's Getinge Q4 sales rise 1.2% organically

Getinge publ AB

27/01/2026 07:10

Overview

Sweden-based medical technology firm's Q4 net sales grew 1.2% organically

Adjusted EBITA margin for Q4 was 17.8%, maintaining full-year margin in line with 2024

Company launched Automatiq, a new sterile reprocessing system, boosting product competitiveness

Outlook

Getinge expects organic sales growth of 3-5% in 2026

Company plans to accelerate development of new products to enhance competitiveness

European deliveries of Cardiosave expected to start in Q2 2026

Result Drivers

HIGHER DEMAND - Increased demand for ECLS-therapy consumables and Acute Care Therapies contributed to performance

PRODUCT INNOVATION - Launch of Automatiq and other product developments enhanced competitiveness

REGULATORY APPROVALS - EU MDR approval for Rotaflow consumables and PMA for iCast stents enhanced competitiveness

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
SEK 4.45
Q4 Adjusted EBITA
SEK 1.81 bln
Q4 Adjusted Gross Profit
SEK 5.04 bln
Q4 Free Cash Flow
SEK 1.19 bln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Getinge AB is SEK236.50, about 11.6% above its January 26 closing price of SEK211.90

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release: ID:nWkrxt9FC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)